Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1995-03-01
2000-10-10
Hutzell, Paula K.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241361, 435 7021, 5303873, 5303881, 5303877, 53038875, 53038885, A61K 39395, C12P 2104, C12P 2108, C07K 1600
Patent
active
061299146
ABSTRACT:
The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.
REFERENCES:
patent: 4444878 (1984-04-01), Paulus
patent: 4658019 (1987-04-01), Kung et al.
patent: 4661586 (1987-04-01), Levy et al.
patent: 4676980 (1987-06-01), Segal et al.
patent: 4714681 (1987-12-01), Reading
patent: 4724213 (1988-02-01), Epstein
patent: 4831117 (1989-05-01), Uckun
patent: 4861589 (1989-08-01), Ju
patent: 4892824 (1990-01-01), Skaletsky
patent: 5582996 (1996-12-01), Curtis
Brissinck, J. (1991) J. Immunol. 147(11):4019-4026.
Burgess et al (J. Cell Biol. 111:2129-2138), 1990.
Lazar et al (Mol & Cell Biol, 8: 1247-1252), 1988.
Tao (J. of Immunol, 143: 2595-2601), 1989.
Bowie et al (Science, 247: 1306-1310), 1990.
Manherimer-Lory et al (J. Exp. Med., 174:1639-1652), 1991.
Brissinck et al., "Bispecific antibodies in lymphoma," Intern. Rev. Immunol., 10:187-194 (1993).
Fitzer-Schiller, The Washington Post, p. D3 (Jan. 19, 1993).
Gershon, Nature, 361:290 (1993).
R. Gingrich et al., "Identification and characterization of a new surface membrane antigen found predominantly on malignant b lymphocytes," Blood, 75(12):2375-2387 (Jun. 15, 1990).
M. Gravelle et al., "The targeting of cd4.sup.+ t lymphocytes to a b cell lymphoma," J. Immunol., 142(11):4079-4084 (Jun. 1, 1989).
Gregoriadis et al., Trends in Biotech., 11:440-442 (1993).
Harris et al., Trends in Biotech., 11:42-44 (1993).
Jung et al., "Induction of cytotoxicity in resting human t lyumphocytes bound to tumor cells by antibody heteroconjugates," Proc. Natl. Acad. Sci. USA, 84:4611-4615 (Jul., 1987).
Kung et al., "Monoclonal antibodies defining distinctive human t cell surface antigens," pp. 347-349 (Oct. 19, 1979).
Lanzavecchia et al., "The use of hybrid hybridomas to target human cytotoxic t lymphocytes," Eur. J. Immunol., 17:105-111 (1987).
S. Moller et al., "Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human t lymphocytes," Cancer Immunol. Immunother., 33:210-216 (1991).
T. Nitta et al., "Bispecific f(ab').sub.2 monomer prepared with anti-cd3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human t cells," Eur. J. Immunol., pp. 1437-1441 (1989).
Oshimi et al., "Increased lysis of patient cd10-positive leukemic cells by t cells coated with anti-cd3 fab' antibody cross-linked to anti-cd10 fab' antibody," Blood, 77(5):1044-1049 (Mar. 1, 1991).
Segal et al., "Targeting of cytotoxic cells with heterocrosslinked antibodies," Cancer Investigation, 6(1):83-92 (1988).
Songsivilai et al., "Bispecific antibody: a tool for diagnosis and treatment of disease," Clin. Exp. Immunol., 79:315-321 (1990).
Staerz et al., "Hybrid antibodies can target sites for attach by t cells," Nature, 314:628-631 (Apr. 18, 1995).
Staerz et al., "Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector t-cell activity," Proc. Natl. Acad. Sci. USA, 83:1453-1457 (Mar., 1986).
Thorpe, Trends in Biotech., 11:40-42 (1993).
Titus et al., "Human t cells targeted with anti-t3 cross-linked to antitumor antibody prevent tumor growth in nude mice," The Journal of Immunology, 138(11):4018-4022 (Jun. 1, 1987).
G. Weiner et al., "Bispecific Anti-idiotype/anti-cd3 antibody therapy of murine b cell lymphoma," J. Immunol., 147:4035-4044 (Dec., 1991).
Gingrich Roger
Link Brian K.
Tso J. Yun
Weiner George
Hutzell Paula K.
Protein Design Labs, Inc.
Ungar Susan
LandOfFree
Bispecific antibody effective to treat B-cell lymphoma and cell does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bispecific antibody effective to treat B-cell lymphoma and cell , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bispecific antibody effective to treat B-cell lymphoma and cell will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2254275